Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

122 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
High internal consistency and efficacy of intravaginal DHEA for vaginal atrophy.
Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Berger L, Martel C, Balser J. Labrie F, et al. Among authors: balser j. Gynecol Endocrinol. 2010 Jul;26(7):524-32. doi: 10.3109/09513590903511547. Gynecol Endocrinol. 2010. PMID: 20459349 Free article. Clinical Trial.
Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia.
Labrie F, Archer DF, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Berger L, Gilbert L, Martel C, Balser J. Labrie F, et al. Among authors: balser j. Climacteric. 2011 Apr;14(2):282-8. doi: 10.3109/13697137.2010.535226. Epub 2011 Jan 18. Climacteric. 2011. PMID: 21244215 Clinical Trial.
Decreased efficacy of twice-weekly intravaginal dehydroepiandrosterone on vulvovaginal atrophy.
Bouchard C, Labrie F, Archer DF, Portman DJ, Koltun W, Elfassi É, Grainger DA, Ayotte N, Cooper TA, Martens M, Waldbaum AS, Labrie C, Côté I, Lavoie L, Martel C, Balser J; VVA Prasterone Group. Bouchard C, et al. Among authors: balser j. Climacteric. 2015;18(4):590-607. doi: 10.3109/13697137.2014.992012. Epub 2015 Mar 3. Climacteric. 2015. PMID: 25511551 Clinical Trial.
Influence of treatment of vulvovaginal atrophy with intravaginal prasterone on the male partner.
Labrie F, Montesino M, Archer DF, Lavoie L, Beauregard A, Côté I, Martel C, Vaillancourt M, Balser J, Moyneur E; other participating Members of the Prasterone Clinical Research Group. Labrie F, et al. Among authors: balser j. Climacteric. 2015;18(6):817-25. doi: 10.3109/13697137.2015.1077508. Epub 2015 Oct 30. Climacteric. 2015. PMID: 26517756 Clinical Trial.
Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women.
Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Berger L, Gilbert L, Martel C, Balser J. Labrie F, et al. Among authors: balser j. Menopause. 2009 Sep-Oct;16(5):923-31. doi: 10.1097/gme.0b013e31819e85c6. Menopause. 2009. PMID: 19424093 Clinical Trial.
Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy.
Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Berger L, Gilbert L, Martel C, Balser J. Labrie F, et al. Among authors: balser j. Menopause. 2009 Sep-Oct;16(5):907-22. doi: 10.1097/gme.0b013e31819e8e2d. Menopause. 2009. PMID: 19436225 Clinical Trial.
Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administration.
Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Bérubé R, Bélanger P, Berger L, Gilbert L, Martel C, Balser J. Labrie F, et al. Among authors: balser j. Menopause. 2009 Sep-Oct;16(5):897-906. doi: 10.1097/gme.0b013e31819e8930. Menopause. 2009. PMID: 19436226 Clinical Trial.
Lack of influence of dyspareunia on the beneficial effect of intravaginal prasterone (dehydroepiandrosterone, DHEA) on sexual dysfunction in postmenopausal women.
Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Gilbert L, Martel C, Balser J. Labrie F, et al. Among authors: balser j. J Sex Med. 2014 Jul;11(7):1766-85. doi: 10.1111/jsm.12517. Epub 2014 Apr 28. J Sex Med. 2014. PMID: 24774442 Clinical Trial.
Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study.
Labrie F, Archer DF, Bouchard C, Girard G, Ayotte N, Gallagher JC, Cusan L, Baron M, Blouin F, Waldbaum AS, Koltun W, Portman DJ, Côté I, Lavoie L, Beauregard A, Labrie C, Martel C, Balser J, Moyneur É; Members of the VVA Prasterone Group. Labrie F, et al. Among authors: balser j. Maturitas. 2015 May;81(1):46-56. doi: 10.1016/j.maturitas.2015.02.005. Epub 2015 Feb 16. Maturitas. 2015. PMID: 25771041 Clinical Trial.
Serum levels of sex steroids and metabolites following 12 weeks of intravaginal 0.50% DHEA administration.
Ke Y, Labrie F, Gonthier R, Simard JN, Bergeron D, Martel C, Vaillancourt M, Montesino M, Lavoie L, Archer DF, Balser J, Moyneur E; other participating Members of the Prasterone Clinical Research Group. Ke Y, et al. Among authors: balser j. J Steroid Biochem Mol Biol. 2015 Nov;154:186-96. doi: 10.1016/j.jsbmb.2015.08.016. Epub 2015 Aug 17. J Steroid Biochem Mol Biol. 2015. PMID: 26291918 Clinical Trial.
122 results